APRE Aprea Therapeutics Inc

Price (delayed)

$0.7784

Market cap

$9.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.5

Enterprise value

-$36.87M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 10
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 32

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor ...

Highlights
The equity has soared by 167% YoY
The quick ratio has soared by 66% from the previous quarter and by 53% YoY
The company's gross profit has shrunk by 90% YoY and by 57% QoQ
Aprea Therapeutics's revenue has plunged by 90% YoY and by 57% from the previous quarter

Key stats

What are the main financial stats of APRE

APRE stock price

How has the Aprea Therapeutics stock price performed over time
Intraday
2.15%
1 week
-16.35%
1 month
-7.42%
1 year
-59.88%
YTD
-8.75%
QTD
2.03%

Financial performance

How have Aprea Therapeutics's revenue and profit performed over time
Revenue
$123,296
Gross profit
$123,296
Operating income
-$12.58M
Net income
-$11.95M
Gross margin
100%
Net margin
-9,696%
The company's operating margin has shrunk by 120% QoQ
The net margin has dropped by 120% since the previous quarter
The company's gross profit has shrunk by 90% YoY and by 57% QoQ
Aprea Therapeutics's revenue has plunged by 90% YoY and by 57% from the previous quarter

Price vs fundamentals

How does APRE's price correlate with its fundamentals

Growth

What is Aprea Therapeutics's growth rate over time

Valuation

What is Aprea Therapeutics stock price valuation
P/E
N/A
P/B
0.21
P/S
92.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-299.03
APRE's EPS is up by 36% year-on-year and by 22% since the previous quarter
The equity has soared by 167% YoY
APRE's P/B is 77% below its 5-year quarterly average of 0.9 and 58% below its last 4 quarters average of 0.5
APRE's P/S is 156% above its last 4 quarters average of 35.5
Aprea Therapeutics's revenue has plunged by 90% YoY and by 57% from the previous quarter

Efficiency

How efficient is Aprea Therapeutics business performance
APRE's return on sales has dropped by 119% since the previous quarter
The company's return on equity rose by 37% QoQ and by 11% YoY
Aprea Therapeutics's ROA has increased by 32% from the previous quarter and by 10% YoY

Dividends

What is APRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APRE.

Financial health

How did Aprea Therapeutics financials performed over time
The company's total assets has surged by 199% QoQ and by 135% YoY
The company's total liabilities has surged by 73% QoQ and by 29% YoY
The debt is 100% smaller than the equity
The equity has soared by 167% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.